BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1907247)

  • 1. Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links.
    Richard S; Tamas C; Sell DR; Monnier VM
    Diabetes; 1991 Aug; 40(8):1049-56. PubMed ID: 1907247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase.
    Nagaraj RH; Prabhakaram M; Ortwerth BJ; Monnier VM
    Diabetes; 1994 Apr; 43(4):580-6. PubMed ID: 8138064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil.
    Nagaraj RH; Monnier VM
    Exp Eye Res; 1990 Oct; 51(4):411-8. PubMed ID: 2120080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen browning and cross-linking are increased in chronic experimental hyperglycemia. Relevance to diabetes and aging.
    Monnier VM; Sell DR; Abdul-Karim FW; Emancipator SN
    Diabetes; 1988 Jul; 37(7):867-72. PubMed ID: 3384185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
    Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
    Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats.
    Suárez G; Rajaram R; Bhuyan KC; Oronsky AL; Goidl JA
    J Clin Invest; 1988 Aug; 82(2):624-7. PubMed ID: 3136193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
    Bank N; Coco M; Aynedjian HS
    Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction.
    Fu MX; Wells-Knecht KJ; Blackledge JA; Lyons TJ; Thorpe SR; Baynes JW
    Diabetes; 1994 May; 43(5):676-83. PubMed ID: 8168645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
    Unakar N; Tsui J; Johnson M
    Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of aldose reductase inhibition on increased basement membrane collagen fluorescence in diabetic rats.
    Cohen MP; Klepser H; Wu VY
    Gen Pharmacol; 1991; 22(4):603-6. PubMed ID: 1936894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
    Frank RN; Amin R; Kennedy A; Hohman TC
    Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.